Immunovant (IMVT) to Report Q3 2025 Financial Results on February 6, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Earnings Announcement: Immunovant will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on February 6, 2026, aiming to keep investors informed of the company's latest developments.
- Conference Call Access: Investors can register online to access the Roivant conference call, ensuring they receive timely updates on financial performance and business insights, thereby enhancing investor engagement.
- Webcast Details: The presentation and webcast information will be available in the 'News & Events' section of Immunovant's website, allowing investors to review the information at their convenience and improving transparency.
- Company Overview: Immunovant is a clinical-stage immunology company focused on autoimmune diseases, dedicated to developing innovative targeted therapies to meet the complex and variable needs of patients, showcasing its leadership in anti-FcRn technology.
Analyst Views on ROIV
Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 27.63 USD with a low forecast of 22.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 22.970
Low
22.00
Averages
27.63
High
33.00
Current: 22.970
Low
22.00
Averages
27.63
High
33.00
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
